You are here

Merck

GSK unveils Keytruda head-to-head data in lung cancer—and they look good at first glance

Fierce Pharma

Wed, 11/30/22 - 07:58 pm

clinical trials

non-small cell lung cancer

Merck to Leverage BigHat's AI Platform in 3 Drug Discovery Programs

BioSpace

Tue, 11/29/22 - 08:25 pm

BigHat Biosciences

artificial intelligence

Merck scores another win for Keytruda, this time in HER2-negative cancer

Endpoints

Tue, 11/22/22 - 04:39 pm

clinical trials

Merck & Co. inks $1.4B blood cancer biotech buyout to muscle in on Bristol Myers, Novartis

Fierce Biotech

Mon, 11/21/22 - 10:34 am

Imago BioSciences

Gossamer could put pressure on Merck

EP Vantage

Fri, 11/11/22 - 10:26 am

United Therapeutics

Sotatercept- the breakthrough PAH has been waiting for?

Clinical Trials Arena

Thu, 11/10/22 - 10:31 am

Is Merck Too Dependent on Keytruda?

Motley Fool

Wed, 11/9/22 - 10:50 am

Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo

Endpoints

Wed, 11/9/22 - 10:38 am

non-small cell lung cancer

Gilead, Arcus slim phase 3 TIGIT trial to take on king Keytruda

Fierce Biotech

Thu, 11/3/22 - 11:10 am

Gilead Sciences

clinical trials

non-small cell lung cancer

A timeline of Ken Frazier’s tenure at Merck

Medical Marketing and Media

Sun, 10/30/22 - 04:13 pm

Kenneth Frazier

Merck CEO Rob Davis has business development on the brain as he builds 'pipeline of the future'

Endpoints

Fri, 10/28/22 - 10:22 am

Kenneth Frazier announces retirement after decades at Merck

Medical Marketing and Media

Thu, 10/27/22 - 08:26 pm

Kenneth Frazier

Merck Stock Jumps As Keytruda Sales Power Q3 Earnings Beat, Profit Forecast Boost

TheStreet.com

Thu, 10/27/22 - 10:46 am

MS Drug Advances from Merck, BMS and More Showcased at ECTRIMS Conference

BioSpace

Wed, 10/26/22 - 06:51 pm

Bristol Myers Squibb

multiple sclerosis

Is Merck Moving Toward Another Blockbuster Drug Launch?

Motley Fool

Wed, 10/26/22 - 10:32 am

Merck fined $38M in Spain for hindering generic competition for NuvaRing

Fierce Pharma

Tue, 10/25/22 - 11:07 pm

anti-competitive scheme

Merck tees up Prevymis filing in kidney transplant recipients after phase 3 trial win

Fierce Pharma

Mon, 10/24/22 - 10:56 am

kidney transplants

clinical trials

Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?

Endpoints

Thu, 10/20/22 - 10:41 am

Bristol Myers Squibb

Things don't look good for NGM's Merck-partnered eye asset as phase 2 fail sends stock plummeting

Fierce Biotech

Mon, 10/17/22 - 11:17 pm

NCM Biopharmaceuticals

clinical trials

age-related macular degeneration

Kineta, Merck Strike Deal to Pair Anti-VISTA Antibody with Keytruda

BioSpace

Mon, 10/17/22 - 10:51 am

monoclonal antibodies

Pages